8-K: Mustang Bio and uBriGene Re-File CFIUS Notice for Cell Processing Facility Sale

Mustang Bio and uBriGene have re-filed their joint voluntary notice with the U.S. Committee on Foreign Investment in the United States (CFIUS) for the sale of Mustang Bio's cell processing facility, marking the second time they've re-filed due to ongoing national security concerns.

Summary

• Mustang Bio and uBriGene are seeking CFIUS clearance for the sale of Mustang Bio's cell processing facility in Worcester, Massachusetts.
• The initial CFIUS review process began with a voluntary notice submitted on August 10, 2023.
• After an initial 45-day review and a subsequent 45-day investigation, CFIUS requested the companies withdraw and re-file their notice on November 13, 2023.
• A new 45-day review period commenced on November 14, 2023, which ended on December 28, 2023.
• The review then transitioned to a second 45-day investigation period, which concluded on February 12, 2024.
• On February 12, 2024, the companies again requested to withdraw and re-file their notice, which was granted.
• A new 45-day review period began on February 13, 2024, and is scheduled to conclude by March 28, 2024.
• If CFIUS does not conclude its review by March 28, 2024, the process will move to a second 45-day investigation phase.

Sentiment

Score: 3

Explanation: The repeated re-filing of the CFIUS notice and the ongoing national security concerns create uncertainty and suggest potential difficulties in completing the transaction, leading to a negative sentiment.

Negatives

• The repeated re-filing of the CFIUS notice suggests ongoing concerns about the transaction.
• The extended review process indicates potential hurdles in completing the sale of the cell processing facility.

Risks

• The transaction may face further delays or potential rejection by CFIUS.
• The ongoing national security concerns could impact the final outcome of the sale.
• The uncertainty surrounding the CFIUS review could affect investor confidence.

Future Outlook

The transaction is subject to ongoing CFIUS review, with a new 45-day review period concluding no later than March 28, 2024. The outcome of the review will determine the future of the sale of the cell processing facility.

Industry Context

The transaction involves the sale of a cell processing facility to a Chinese contract development and manufacturing organization, which is a sensitive area given the current geopolitical climate and focus on national security. The scrutiny from CFIUS reflects the increasing attention on foreign investment in critical infrastructure and technologies.

Comparison to Industry Standards

• CFIUS reviews are becoming increasingly common for transactions involving foreign entities acquiring US assets, particularly in sensitive sectors like biotechnology and manufacturing.
• The repeated re-filing of the notice suggests a higher level of scrutiny than typical, potentially due to the nature of the technology or the buyer's origin.
• Other similar transactions involving foreign acquisitions of US biotech assets have also faced extended CFIUS reviews, indicating a trend of increased caution.

Stakeholder Impact

• Shareholders may experience uncertainty due to the ongoing CFIUS review.
• Employees at the cell processing facility may be affected by the potential sale.
• The outcome of the transaction could impact the company's future strategic direction.

Next Steps

• CFIUS will continue its review of the transaction.
• The current 45-day review period will conclude no later than March 28, 2024.
• If the review is not completed by March 28, 2024, a second 45-day investigation period will commence.

Key Dates

Keywords

CFIUS, Mustang Bio, uBriGene, cell processing facility, national security, transaction, review, investigation, sale